B
BioSpace
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
0:00-19:08
Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.
Publisher
BioSpace
Published
August 19, 2026
Duration
19 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#amylyxsredemption #summitssurvivalwoes #definiumsanxietywin #lifesciences
